NGS testing for ovarian cancer – pro
NCCN does not recommend molecular profiling, unlike for several other common cancer types. NCCN (National Comprehensive Cancer Network): Recommends germline testing for several mutations, f.e. BRCA1 and 2, and others, but not a molecular profile. ESMO recently, in 2024, updated its recommendation in 2024 to recommend routine testing for advanced breast cancer, GIST, sarcoma, thyroid cancer, and cancer of unknown primary, and metastatic cancers where access to matched therapies is availabl, but not specifically Ovarian Cancer.
NCCN OV-1, 2025 and MS-7.
Harbin LM, Gallion HH, Allison DB, Kolesar JM. Next Generation Sequencing and Molecular Biomarkers in Ovarian Cancer-An Opportunity for Targeted Therapy. Diagnostics (Basel). 2022 Mar 29;12(4):842. doi: 10.3390/diagnostics12040842. PMID: 35453890; PMCID: PMC9030726.
M.F. Mosele, C.B. Westphalen, A. Stenzinger, Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group. ESMO Annals in ONcology Volume 35, Issue 7p588-606July 2024.